JP2018537514A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018537514A5 JP2018537514A5 JP2018531667A JP2018531667A JP2018537514A5 JP 2018537514 A5 JP2018537514 A5 JP 2018537514A5 JP 2018531667 A JP2018531667 A JP 2018531667A JP 2018531667 A JP2018531667 A JP 2018531667A JP 2018537514 A5 JP2018537514 A5 JP 2018537514A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- bladder
- use according
- hal
- light
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims 24
- 206010005003 Bladder cancer Diseases 0.000 claims 5
- 239000007788 liquid Substances 0.000 claims 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims 3
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 3
- 238000009098 adjuvant therapy Methods 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 201000005112 urinary bladder cancer Diseases 0.000 claims 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 2
- 239000007864 aqueous solution Substances 0.000 claims 2
- 238000009799 cystectomy Methods 0.000 claims 2
- -1 hexyl 5-ALA ester Chemical class 0.000 claims 2
- 210000003205 muscle Anatomy 0.000 claims 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 2
- XMEKHKCRNHDFOW-UHFFFAOYSA-N O.O.[Na].[Na] Chemical compound O.O.[Na].[Na] XMEKHKCRNHDFOW-UHFFFAOYSA-N 0.000 claims 1
- 229910019142 PO4 Inorganic materials 0.000 claims 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 1
- 238000001802 infusion Methods 0.000 claims 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 claims 1
- 235000019796 monopotassium phosphate Nutrition 0.000 claims 1
- 238000009099 neoadjuvant therapy Methods 0.000 claims 1
- 239000010452 phosphate Substances 0.000 claims 1
- 239000008363 phosphate buffer Substances 0.000 claims 1
- 239000008055 phosphate buffer solution Substances 0.000 claims 1
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 claims 1
- 239000011780 sodium chloride Substances 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1522309.2A GB201522309D0 (en) | 2015-12-17 | 2015-12-17 | Use |
| GB1522309.2 | 2015-12-17 | ||
| PCT/EP2016/081803 WO2017103283A1 (en) | 2015-12-17 | 2016-12-19 | Neoadjuvant therapy for bladder cancer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018537514A JP2018537514A (ja) | 2018-12-20 |
| JP2018537514A5 true JP2018537514A5 (enExample) | 2020-02-06 |
| JP6926086B2 JP6926086B2 (ja) | 2021-08-25 |
Family
ID=55311159
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018531667A Active JP6926086B2 (ja) | 2015-12-17 | 2016-12-19 | 膀胱癌のための術前補助療法 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US10556010B2 (enExample) |
| EP (1) | EP3389717B9 (enExample) |
| JP (1) | JP6926086B2 (enExample) |
| KR (1) | KR102787188B1 (enExample) |
| CN (2) | CN119345359A (enExample) |
| AU (1) | AU2016372573B2 (enExample) |
| BR (1) | BR112018012009B1 (enExample) |
| DK (1) | DK3389717T3 (enExample) |
| ES (1) | ES3015668T3 (enExample) |
| FI (1) | FI3389717T3 (enExample) |
| GB (1) | GB201522309D0 (enExample) |
| PL (1) | PL3389717T3 (enExample) |
| WO (1) | WO2017103283A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201522311D0 (en) * | 2015-12-17 | 2016-02-03 | Photocure Asa | Use |
| GB201522309D0 (en) * | 2015-12-17 | 2016-02-03 | Photocure Asa | Use |
| MX2020005692A (es) * | 2017-12-01 | 2020-09-25 | Sbi Pharmaceuticals Co Ltd | Composicion farmaceutica para mejorar el efecto antitumoral mediante el inhibidor del punto de control inmunitario. |
| KR102441358B1 (ko) | 2020-09-14 | 2022-09-06 | 주식회사 아파트엔 | 아파트의 지수화를 통한 아파트 투자 가치 평가 시스템 |
| EP4676462A1 (en) | 2023-03-07 | 2026-01-14 | Photocure ASA | Therapy for bladder cancer |
| WO2026052815A1 (en) | 2024-09-05 | 2026-03-12 | Photocure Asa | Use of hal in a method for predicting bladder cancer immunotherapy response |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7530461B2 (en) * | 1995-03-10 | 2009-05-12 | Photocure Asa | Esters of 5-aminolevulinic acid as photosensitizing agents in photochemotherapy |
| NZ303251A (en) | 1995-03-10 | 2000-10-27 | Photocure Asa | Use of esters of 5-aminolevulinic acid as photosensitising agents in photochemotherapy |
| GB0018528D0 (en) * | 2000-07-27 | 2000-09-13 | Photocure Asa | Compounds |
| PT1537878E (pt) | 2002-07-03 | 2010-11-18 | Ono Pharmaceutical Co | Composições de imunopotenciação |
| GB0406917D0 (en) | 2004-03-26 | 2004-04-28 | Photocure Asa | Compounds |
| PL2161336T5 (pl) | 2005-05-09 | 2017-10-31 | Ono Pharmaceutical Co | Ludzkie przeciwciała monoklonalne przeciwko białku Programmed Death 1 (PD-1) oraz sposoby leczenia raka z zastosowaniem samych przeciwciał anty-PD-1 lub w połączeniu z innymi środkami immunoterapeutycznymi |
| CA2612241C (en) | 2005-07-01 | 2018-11-06 | Medarex, Inc. | Human monoclonal antibodies to programmed death ligand 1 (pd-l1) |
| KR101586617B1 (ko) | 2007-06-18 | 2016-01-20 | 머크 샤프 앤 도메 비.브이. | 사람 프로그램된 사멸 수용체 ｐｄ-1에 대한 항체 |
| US8168757B2 (en) | 2008-03-12 | 2012-05-01 | Merck Sharp & Dohme Corp. | PD-1 binding proteins |
| EP4209510B1 (en) | 2008-12-09 | 2024-01-31 | F. Hoffmann-La Roche AG | Anti-pd-l1 antibodies and their use to enhance t-cell function |
| KR101797780B1 (ko) | 2009-06-11 | 2017-11-14 | 포토큐어 에이에스에이 | 반고체 조성물 및 약제학적 제품 |
| EP2739358B1 (en) | 2011-08-01 | 2018-11-28 | F.Hoffmann-La Roche Ag | Methods of treating cancer using pd-1 axis binding antagonists and mek inhibitors |
| US9624298B2 (en) | 2011-11-28 | 2017-04-18 | Merck Patent Gmbh | Anti-PD-L1 antibodies and uses thereof |
| JP6312659B2 (ja) | 2012-05-31 | 2018-04-18 | ジェネンテック， インコーポレイテッド | Ｐｄ−１系結合アンタゴニスト及びｖｅｇｆアンタゴニストを用いた癌の治療方法 |
| US8927761B2 (en) | 2012-06-28 | 2015-01-06 | Photocure Asa | Form of hexyl-5-aminolevulinate hydrochloride and methods of using the same |
| RU2635563C2 (ru) * | 2012-08-03 | 2017-11-14 | ФотоКьюэр АСА | Соединения |
| GB201522309D0 (en) * | 2015-12-17 | 2016-02-03 | Photocure Asa | Use |
| CN109010850B (zh) * | 2018-08-01 | 2021-10-22 | 上海师范大学 | 一种负载姜黄素的葡聚糖修饰的钆掺杂的空心介孔二氧化硅纳米材料的制备方法及应用 |
-
2015
- 2015-12-17 GB GBGB1522309.2A patent/GB201522309D0/en not_active Ceased
-
2016
- 2016-12-19 CN CN202411498667.9A patent/CN119345359A/zh active Pending
- 2016-12-19 CN CN201680079674.2A patent/CN108601836A/zh active Pending
- 2016-12-19 EP EP16819894.3A patent/EP3389717B9/en active Active
- 2016-12-19 JP JP2018531667A patent/JP6926086B2/ja active Active
- 2016-12-19 AU AU2016372573A patent/AU2016372573B2/en active Active
- 2016-12-19 DK DK16819894.3T patent/DK3389717T3/da active
- 2016-12-19 BR BR112018012009-0A patent/BR112018012009B1/pt active IP Right Grant
- 2016-12-19 FI FIEP16819894.3T patent/FI3389717T3/fi active
- 2016-12-19 US US16/063,185 patent/US10556010B2/en active Active
- 2016-12-19 WO PCT/EP2016/081803 patent/WO2017103283A1/en not_active Ceased
- 2016-12-19 KR KR1020187020006A patent/KR102787188B1/ko active Active
- 2016-12-19 ES ES16819894T patent/ES3015668T3/es active Active
- 2016-12-19 PL PL16819894.3T patent/PL3389717T3/pl unknown
-
2020
- 2020-01-21 US US16/748,332 patent/US11311620B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014094963A5 (enExample) | ||
| RU2013121788A (ru) | Ингибиторы репликации вич | |
| NZ609719A (en) | Pharmaceutical composition | |
| JP2013501224A5 (enExample) | ||
| JP2012525393A5 (enExample) | ||
| AR074826A1 (es) | Regimen de dosificacion para un agonista de los receptores de s1p | |
| RU2012118974A (ru) | Комбинации ингибитора pi3k и ингибитора мек | |
| JP2017518302A5 (enExample) | ||
| JP2015511609A5 (enExample) | ||
| JP2020507589A5 (enExample) | ||
| FI3389717T3 (fi) | Neoadjuvanttihoito virtsarakon syöpää varten | |
| RU2014150942A (ru) | Лечение побочных эффектов в виде моторных и двигательных расстройств, связанных с лечением болезни паркинсона | |
| AR045956A1 (es) | Multiparticulas de pantoprazol y formulacion que las contiene | |
| JP2016512210A5 (enExample) | ||
| JP2018538308A5 (enExample) | ||
| JP2019501161A5 (enExample) | ||
| RU2008105590A (ru) | ПРИМЕНЕНИЕ 3, 11b-ЦИС-ДИГИДРОТЕТРАБЕНАЗИНА ДЛЯ ЛЕЧЕНИЯ СИМПТОМОВ БОЛЕЗНИ ГЕНТИНГТОНА | |
| JP2016527202A5 (enExample) | ||
| JP2017513927A5 (enExample) | ||
| EP4578461A3 (en) | Methods of treating parkinsons disease by administration of apomorphine to an oral mucosa | |
| JP2017509623A5 (enExample) | ||
| RU2013131241A (ru) | Композиции, содержащие ингибитор рi3к и ингибитор мек, а также их применение для лечения рака | |
| RU2018123834A (ru) | Способ фотодинамической терапии (фдт) для рака мочевого пузыря | |
| JP2018508523A5 (enExample) | ||
| RU2007118691A (ru) | Применение 4-трифторметилфениламида (z)-2-циано-3-гидрокси-бут-2-еновой кислоты для лечения воспалительных заболеваний кишечника |